Lead Product(s): Koate DVI
Therapeutic Area: Genetic Disease
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: WuXi Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 16, 2020
First drug product facility in Europe to complement WuXi Biologicsâ€™ existing commercial manufacturing capacities. WuXi Biologics will be the back-up manufacturer for Kovaltryâ„¢ of Bayer.